SUNITINIB TARO 12.5 MG Israel - English - Ministry of Health

sunitinib taro 12.5 mg

taro international ltd, israel - sunitinib - hard capsule - sunitinib 12.5 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

SUNITINIB TARO 25 MG Israel - English - Ministry of Health

sunitinib taro 25 mg

taro international ltd, israel - sunitinib - hard capsule - sunitinib 25 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

SUNITINIB TARO 37.5 MG Israel - English - Ministry of Health

sunitinib taro 37.5 mg

taro international ltd, israel - sunitinib - hard capsule - sunitinib 37.5 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

SUNITINIB TARO 50 MG Israel - English - Ministry of Health

sunitinib taro 50 mg

taro international ltd, israel - sunitinib - hard capsule - sunitinib 50 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Sunitinib Sandoz sunitinib 50 mg capsule bottle Australia - English - Department of Health (Therapeutic Goods Administration)

sunitinib sandoz sunitinib 50 mg capsule bottle

sandoz pty ltd - sunitinib, quantity: 50 mg - capsule - excipient ingredients: magnesium stearate; microcrystalline cellulose; gelatin; povidone; iron oxide red; mannitol; titanium dioxide; croscarmellose sodium; iron oxide black; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Sunitinib Sandoz sunitinib 37.5 mg capsule bottle Australia - English - Department of Health (Therapeutic Goods Administration)

sunitinib sandoz sunitinib 37.5 mg capsule bottle

sandoz pty ltd - sunitinib, quantity: 37.5 mg - capsule - excipient ingredients: povidone; croscarmellose sodium; titanium dioxide; magnesium stearate; microcrystalline cellulose; gelatin; mannitol; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Sunitinib Sandoz sunitinib 12.5 mg capsule blister Australia - English - Department of Health (Therapeutic Goods Administration)

sunitinib sandoz sunitinib 12.5 mg capsule blister

sandoz pty ltd - sunitinib, quantity: 12.5 mg - capsule - excipient ingredients: titanium dioxide; povidone; microcrystalline cellulose; iron oxide red; gelatin; mannitol; magnesium stearate; croscarmellose sodium; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Sunitinib Sandoz sunitinib 25 mg capsule bottle Australia - English - Department of Health (Therapeutic Goods Administration)

sunitinib sandoz sunitinib 25 mg capsule bottle

sandoz pty ltd - sunitinib, quantity: 25 mg - capsule - excipient ingredients: magnesium stearate; gelatin; croscarmellose sodium; mannitol; povidone; microcrystalline cellulose; iron oxide red; titanium dioxide; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Sunitinib Sandoz sunitinib 25 mg capsule blister Australia - English - Department of Health (Therapeutic Goods Administration)

sunitinib sandoz sunitinib 25 mg capsule blister

sandoz pty ltd - sunitinib, quantity: 25 mg - capsule - excipient ingredients: gelatin; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; povidone; mannitol; titanium dioxide; iron oxide red; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Sunitinib Sandoz sunitinib 37.5 mg capsule blister Australia - English - Department of Health (Therapeutic Goods Administration)

sunitinib sandoz sunitinib 37.5 mg capsule blister

sandoz pty ltd - sunitinib, quantity: 37.5 mg - capsule - excipient ingredients: povidone; gelatin; microcrystalline cellulose; magnesium stearate; mannitol; titanium dioxide; croscarmellose sodium; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - ? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).